IL2 and type 1 diabetes mellitus: Using a human PDC consisting of a human thioredoxin-human IL-2 fusion protein conjugated to 3 molecules of MLN4924, we were able to show that treatment with PDC could restore the suppressive function of T1D patient Tregs that normally exhibit significantly reduced suppressive function compared to Tregs of healthy controls (Figure 6).